May 15 (Reuters) -
JCR PHARMACEUTICALS CO LTD
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to Six months to
Mar 31, 2009 Mar 31, 2008 Mar 31, 2010 Sep 30, 2009
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECASTS H1 FORECASTS Sales 11.77 11.28 11.90 5.80
(+4.3 pct) (+38.5 pct) (+1.1%) (+15.5%) Operating 432 mln 113 mln 500 mln 110 mln
(+280.8 pct) (+15.7%) Recurring 553 mln 530 mln 510 mln 130 mln
(+4.4 pct) (-7.9%) Net 462 mln 251 mln 280 mln 80 mln
(+84.2 pct) (-39.5%) EPS Y17.22 Y9.26 Y10.54 Y3.01 Diluted EPS Y17.22 Y9.26 Annual div Y10.00 Y10.00 Y10.00 -Q2 div Y5.00 Y5.00 Y5.00 -Q4 div Y5.00 Y5.00 Y5.00
NOTE - JCR Pharmaceuticals Co Ltd is a leading firm in the field of human-derived biological active substance.
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half dividend and Q4 to the second-half dividend announced before a new corporate law in 2006 allowed companies to pay and report dividends on a quarterly basis.
For latest earnings estimates made by Toyo Keizai, please double click on 4552.TK1.